Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Aug 21;15:1444007. doi: 10.3389/fimmu.2024.1444007

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2024 Rayford, Gärtner, Ramnefjell, Lorens, Micklem, Aanerud and Engelsen

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

AXL expression on tumor cells and tumor-infiltrating immune cells is related to outcome measurements in ICI-treated NSCLC patients. (A) Overall Survival (OS) of 2L-ICI patients stratified by high- vs low tAXL expression using an optimal cutpoint of Hscore >105 (95% confidence-interval in brackets). (B, C) Boxplots of AXL Hscores in tumor samples obtained before or after 1L-chemotherapy, stratified by primary chemoresistance (B) or biopsy timepoint (C). (D, E) Boxplots of AXL Hscores in 1L-patients stratified by disease control (D) and within 1L-subgroups with or without radiotherapy (RT) before/during ICI treatment (E). (F) OS of all AXL IC-evaluable patients (n = 107) stratified by presence of AXL+ tumor-infiltrating immune cells (AXL IC>0). p-values in boxplots and Kaplan-Meier plots from Mann-Whitney U test and log-rank test, respectively.